Correlation between ovarian chocolate cyst and serum carbohydrate antigen 125 level and the effect of ultrasound-guided interventional sclerotherapy on serum carbohydrate antigen 125 level

AimThis study was to investigate the correlation between ovarian chocolate cysts and serum carbohydrate antigen (CA)-125 levels and to demonstrate the effect of ultrasound-guided interventional sclerotherapy (UGIS) on serum CA-125 levels. MethodsBased on the serum CA-125 level, as determined by chemiluminescence detection prior to UGIS, 105 patients with ovarian chocolate cysts were divided into the normal group (CA-12535U/mL, 45 patients) and the abnormal group (35U/mL<CA-125200U/mL, 60 patients). There were six clinical indicators including age, disease duration, dysmenorrhea history, child-bearing history, abortion history and surgical history. The ultrasonography characteristics were cyst diameter, cyst wall thickness and the side on which the cyst occurred. The correlations between serum CA-125 levels pretreatment and the clinical indicators and ultrasonography characteristics was analyzed. The serum CA-125 levels pretreatment, 3 months post-treatment and 6 months post-treatment were compared. ResultsThe pretreatment serum CA-125 levels of the 105 patients positively correlated with disease duration (r=0.3932, P=0.0040), dysmenorrhea history (r=0.2351, P=0.0111), cyst diameter (r=0.3415, P<0.0001) and cyst wall thickness (r=0.4263, P<0.0001). Compared with the pretreatment level, the mean serum CA-125 level in the abnormal group at 3 months post-treatment was significantly lower (P<0.01), and at 6 months post-treatment, the mean serum CA-125 level had decreased to a normal level (P<0.01). ConclusionUGIS significantly decreased abnormal serum CA-125 levels in patients with ovarian chocolate cysts.